Blueprint Medicines Corp
NASDAQ:BPMC

Watchlist Manager
Blueprint Medicines Corp Logo
Blueprint Medicines Corp
NASDAQ:BPMC
Watchlist
Price: 94.15 USD -2.56% Market Closed
Market Cap: 6B USD
Have any thoughts about
Blueprint Medicines Corp?
Write Note

Relative Value

The Relative Value of one BPMC stock under the Base Case scenario is 165.34 USD. Compared to the current market price of 94.15 USD, Blueprint Medicines Corp is Undervalued by 43%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BPMC Relative Value
Base Case
165.34 USD
Undervaluation 43%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
58
vs Industry
28
Median 3Y
16.8
Median 5Y
16.8
Industry
7.7
Forward
11.5
vs History
vs Industry
Median 3Y
-6.9
Median 5Y
-6.9
Industry
22.7
Forward
-93.3
vs History
vs Industry
Median 3Y
-11.4
Median 5Y
-10.1
Industry
21.6
vs History
vs Industry
Median 3Y
-12
Median 5Y
-10.7
Industry
25.2
vs History
9
vs Industry
3
Median 3Y
7.5
Median 5Y
5.9
Industry
2.5
vs History
52
vs Industry
25
Median 3Y
14.5
Median 5Y
14.5
Industry
7.7
Forward
10.6
vs History
46
vs Industry
22
Median 3Y
15.4
Median 5Y
12.8
Industry
9
vs History
vs Industry
Median 3Y
-6.3
Median 5Y
-6.1
Industry
4.2
Forward
-27.9
vs History
vs Industry
Median 3Y
-6.1
Median 5Y
-6.1
Industry
4.1
Forward
-24.1
vs History
vs Industry
Median 3Y
-9.9
Median 5Y
-8.1
Industry
5.7
vs History
vs Industry
Median 3Y
-9.7
Median 5Y
-7.9
Industry
3.6
vs History
12
vs Industry
15
Median 3Y
7.6
Median 5Y
7.6
Industry
4.6

Multiples Across Competitors

BPMC Competitors Multiples
Blueprint Medicines Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Blueprint Medicines Corp
NASDAQ:BPMC
5.9B USD 13.7 -46.4 -21 -20
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD 10.9 -242.3 24.1 25.3
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD 5.9 17.5 15.9 17.7
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.8B EUR 18.7 -131 -105.5 -76.9
P/E Multiple
Earnings Growth
US
Blueprint Medicines Corp
NASDAQ:BPMC
Average P/E: 208.2
Negative Multiple: -46.4
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -242.3
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -131 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Blueprint Medicines Corp
NASDAQ:BPMC
Average EV/EBITDA: 17.2
Negative Multiple: -21
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.9
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.5 N/A
EV/EBIT Multiple
EBIT Growth
US
Blueprint Medicines Corp
NASDAQ:BPMC
Average EV/EBIT: 22.5
Negative Multiple: -20
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.3
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.9 N/A

See Also

Discover More
Back to Top